Evogene Ltd. (EVGN): history, ownership, mission, how it works & makes money

A Brief History of Evogene Ltd. (EVGN)

Overview

Evogene Ltd. was established in 2002, focusing on the development of computational biology and molecular biology to enhance crop productivity and improve agricultural practices. The company is headquartered in Rehovot, Israel, and employs advanced technology to develop products for the agricultural market.

Initial Public Offerings

Evogene went public on the NASDAQ in July 2014, raising approximately $36 million in its initial public offering (IPO). The shares were listed under the ticker symbol EVGN.

Financial Performance

As per the latest financial reports for the year 2022, Evogene generated revenues amounting to $1.2 million. Over the same period, the total operating expenses were reported at $19 million, leading to a net loss of approximately $17.7 million.

Strategic Partnerships

Evogene has established various collaborations and strategic partnerships. In 2021, the company partnered with Bayer to advance the development of products in the field of biologicals through Evogene’s proprietary technology.

Research and Development Focus

The company focuses on several innovative platforms, including:

• Ag-Data - a platform for crop disease resistance and yield.
• GeneRator - a technology for gene discovery and development.
• Microbiome - aimed at enhancing plant health and productivity through microbial products.

Market Position and Valuation

As of October 2023, Evogene’s market capitalization is approximately $80 million. The stock price has seen fluctuations, with a 52-week range of $0.54 to $1.88.

Outlook for the Future

Evogene has outlined an aggressive roadmap to further its product pipeline and enhance its technological capabilities. The company continues to seek investment and collaboration opportunities to improve its market offerings in agricultural biotechnology.

A Who Owns Evogene Ltd. (EVGN)

Shareholder Structure

Evogene Ltd. has a diverse shareholder base that includes institutional investors, retail investors, and company insiders. As of the latest available data, here is the breakdown of ownership:

Major Institutional Investors

The following table outlines the top institutional shareholders of Evogene Ltd.:

Company Leadership

The executive leadership team also holds significant equity in the company. Below are the key executive officers and their ownership stakes:

Recent Share Performance

As of the end of Q3 2023, Evogene Ltd. (EVGN) has reported the following financial metrics:

Recent Developments

In a recent press release, Evogene Ltd. announced an increase in partnerships for its technology development initiatives, which is projected to enhance shareholder value significantly. Below is a summary of recent key partnerships:

Conclusion of Ownership Analysis

The ownership structure of Evogene Ltd. reflects a combination of institutional investment and active participation from company management. The financial performance metrics indicate a growing interest in the company's future prospects.

Evogene Ltd. (EVGN) Mission Statement

Corporate Overview

Evogene Ltd. is a biotechnology company that focuses on developing innovative solutions for the agricultural industry. The company employs advanced computational biology to enhance the productivity and resilience of crops. As of October 2023, Evogene has been actively involved in creating new strains of crops and traits that aim to tackle global food security challenges.

Mission Statement

Evogene’s mission is to become a leading force in revolutionizing agriculture through the integration of computational biology and genetic technologies. The company aims to address the increasing demand for sustainable agricultural practices and food supply.

Core Values

• Innovation: Commitment to continuous research and technological advancement.
• Sustainability: Focus on developing eco-friendly agricultural solutions.
• Collaboration: Building partnerships with industry leaders and academic institutions.

Financial Performance

As of Q3 2023, Evogene reported the following financial data:

Strategic Goals

Evogene's strategic goals for the next five years include:

• Increase market presence in the crop protection segment.
• Develop partnerships to expand R&D capabilities.
• Launch at least five new products by 2025.

Recent Initiatives

In 2023, Evogene launched several notable initiatives:

• Collaboration with leading seed companies to enhance crop traits.
• Investment in AI-driven platforms for data analysis in agriculture.
• Participation in global forums focusing on sustainable farming practices.

Impact on Agriculture

Evogene’s innovations are expected to significantly impact:

• Crop yield improvement by up to 20%.
• Reduction in pesticide usage through resistant traits.
• Enhanced resilience against climate impact.

Conclusion

Evogene Ltd. continues to position itself at the forefront of agricultural biotechnology, leveraging cutting-edge technology to fulfill its mission of transforming agriculture for a sustainable future.

How Evogene Ltd. (EVGN) Works

Corporate Overview

Evogene Ltd. (NASDAQ: EVGN) is a biotechnology company focused on the fields of agriculture and food. The company employs computational biology to enhance crop performance and productivity.

Business Model

Evogene operates on a collaborative business model, partnering with agribusinesses to develop and commercialize products. This collaboration facilitates a faster route to market for innovations.

• Business Segments:
  • Agricultural Biologicals
  • Seed and Trait Development
  • Crop Protection
• Revenue Streams:
  • Licensing Agreements
  • Joint Ventures
  • Research and Development Services

Financial Performance

For the fiscal year ending December 31, 2022, Evogene reported significant financial data:

Technological Innovations

Evogene employs its proprietary technology platforms, which include:

• GeneRator: A platform for discovering genes linked to key agricultural traits.
• Microbiome: Focuses on the plant microbiome as a source for agricultural products.
• Computational Biology: Integrating big data analytics to drive plant breeding and improvement.

Strategic Alliances

Evogene has entered into several strategic partnerships to enhance its product offerings:

Market Position

Evogene operates within a competitive landscape, facing challenges and opportunities from various entities:

• Key Competitors:
  • Benson Hill
  • Corteva Agriscience
  • Regeneron Pharmaceuticals
• Market Trends:
  • Increased demand for sustainable agriculture solutions
  • Growing investment in biotech innovations

Recent Developments

As of Q3 2023, Evogene has made notable strides in product development and partnerships:

• Announced the successful trials of new crop varieties with improved resistance to pests.
• Expanded collaboration with leading agricultural firms for technology integration.
• Reported an increase in R&D investment, totaling $8 million for the fiscal year.

How Evogene Ltd. (EVGN) Makes Money

Revenue Streams

Evogene Ltd. primarily generates revenue through multiple streams, notably focusing on the agriculture and biotechnology sectors.

Partnerships and Collaborations

Evogene collaborates with various multinational corporations to develop agricultural solutions. For instance, the company entered a partnership with Syngenta in 2020 for the development of novel traits in crops.

Product Offerings

The main product lines include:

• Plant Genetic Solutions: Developing seed traits that enhance yield and resistance.
• Microbial Solutions: Offering bio-based products that promote soil health.
• Crop Protection: Products aimed at protecting crops from pests and diseases.

Financial Performance

For the fiscal year ending December 2022, Evogene reported revenues of $1.5 million, showing a decrease from $2.4 million in 2021.

The company's net loss for the same period was $20.9 million, compared to a net loss of $18.7 million in 2021.

Market Cap and Stock Performance

As of October 2023, Evogene’s market capitalization stands at approximately $63 million.

The stock price has fluctuated significantly, ranging from $0.55 to $1.10 within the last year.

Research and Development Investments

Evogene allocates a substantial portion of its budget to R&D, with expenditures of approximately $13 million for the year ending December 2022.

This investment supports the development of innovative technologies and products, aiming to capture a larger share of the agricultural biotechnology market.

Table of Financial Data

Future Growth Potential

Evogene is strategically positioned to capitalize on the growing need for sustainable agricultural practices. The global agricultural biotechnology market is projected to reach $28 billion by 2027, growing at a CAGR of 10.5%.